Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265473 · ClinicalTrials.gov registry record · Phase 1
MGA031, Sirolimus and Tacrolimus in Islet Transplantation
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00265473 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 5 participants.
The verdict
NCT00265473, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This clinical trial is designed to extend the observations made in our pilot clinical trial (IND 8971, Study #1) on the safety and efficacy of immunotherapy with the anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with sirolimus and tacrolimus in preventing rejection and autoimmune destruction of deceased donor pancreatic islet transplants in type 1 diabetic recipients.
Interventions
- BIOLOGICAL Allogeneic Islets of Langerhans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265473
The ClinicalTrials.gov registry entry for NCT00265473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic Islets of Langerhans is the first listed.
NCT00265473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265473 about?
NCT00265473 is a clinical study titled "MGA031, Sirolimus and Tacrolimus in Islet Transplantation". This clinical trial is designed to extend the observations made in our pilot clinical trial (IND 8971, Study #1) on the safety and efficacy of immunotherapy with the anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with sirolimus and tacrolimus in preventing rejecti...
What is the current status of trial NCT00265473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2005-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00265473?
The interventions under investigation include: Allogeneic Islets of Langerhans (BIOLOGICAL).
Who is sponsoring clinical trial NCT00265473?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.